October 2015 in “Digital Library of Theses and Dissertations (Universidade de São Paulo)” Finasteride reduces prostate size and PSA levels in young men with hair loss.
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
January 2004 in “Chinese Journal of New Drugs and Clinical Remedies”
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
1 citations
,
January 2003 in “Zhongguo yaoke daxue xuebao” The two finasteride tablet formulations are bioequivalent.
January 2013 in “Zhonghua linchuang yishi zazhi” Taking finasteride for over a month before surgery reduces blood loss during TURP.
18 citations
,
July 2009 in “Drug Metabolism and Disposition” Finasteride breakdown products found in bile and urine, helps understand drug safety and effectiveness.
September 1999 in “PubMed” Finasteride effectively thickens hair in men with minimal side effects.
2 citations
,
January 2010 Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.
3 citations
,
October 1993 in “Endocrinology” 235 citations
,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
7 citations
,
November 2014 in “Clinical Therapeutics” Finasteride and tamsulosin hydrochloride can be safely taken together without significant interaction.
9 citations
,
January 2017 in “Farmacia” Finasteride can still be used for hair loss with careful consideration of side effects and patient information.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
20 citations
,
December 1995 in “Journal of Chromatography B: Biomedical Sciences and Applications” Accurate method measures finasteride levels in human plasma using gas chromatography-mass spectrometry.
April 2023 in “Medicina Clínica (english Edition)” 1 citations
,
January 2012
24 citations
,
February 2000 in “Journal of Chromatography B: Biomedical Sciences and Applications” Valid method measures finasteride in plasma, simple, fast, and affordable.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.
109 citations
,
April 2000 in “European Urology” Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
44 citations
,
January 2012 in “Food and chemical toxicology” Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.
November 2025 in “JAAD Case Reports” Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.
10 citations
,
June 1998 in “PubMed” Finasteride significantly reduces DHT levels in male dogs without affecting testosterone levels, suggesting it could be used to treat benign prostatic hypertrophy in dogs weighing 10 to 50 kilograms.
January 2011 in “Reactions Weekly”
7 citations
,
July 1995 in “PubMed” Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.
December 2020 in “Journal of Skin and Sexually Transmitted Diseases” No strong link between testosterone or DHEAS levels and acne or hair loss in females.
March 2026 in “Translational Andrology and Urology” Finasteride 1 mg may help prevent prostate issues, but more research is needed to confirm its benefits.
17 citations
,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
October 2025 in “Reactions Weekly”